ArticleFrontiers in immunology2025
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- SLC25A12 mitigates mitochondrial dysfunction in myoblast senescence, and alleviates cuproptosis-related changes under copper stress.Biology direct · 2026Article
- Haplotype‑resolved comparison of transcription factor superfamilies between wild and cultivated autotetraploid green jujube and prioritization of candidate transcription factors via machine learning.The plant genome · 2026Article
- CD48 and CXCR4 as immune-associated biomarkers in periodontitis: an integrative analysis and validation study.Frontiers in immunology · 2026Article
- The role and function of CTLA-4 in Sjögren's syndrome.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary Sjögren's syndrome (pSS) is a chronic systemic autoimmune disorder. However, current diagnostic methods remain limited, necessitating the exploration of non-invasive diagnostic markers with higher specificity. Methods: This study integrated two GEO expression datasets to identify differentially expressed genes (DEGs) specific to pSS (distinct from SLE) and applied LASSO, XGBoost, RF, and SVM-RFE algorithms to screen candidate genes. Correlation and interaction network analyses were performed, followed by construction and validation of a diagnostic nomogram. The model's differential diagnostic ability was validated in IgG4-RD, RA, SLE, and SSc cohorts. Additionally, candidate genes and the diagnostic model were experimentally validated using RT-qPCR in clinical samples. Results: Three candidate genes ( Conclusions:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.